TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Actinium Pharmaceuticals ( (ATNM) ) is now available.
On November 26, 2025, Actinium Pharmaceuticals held its annual meeting of stockholders, where Ajit S. Shetty and June S. Almenoff were re-elected as Class III directors for a term expiring in 2028. The meeting also saw the ratification of CBIZ as the independent public accounting firm for 2025 and approval of executive compensation-related proposals, reflecting continued shareholder support for the company’s governance and strategic direction.
The most recent analyst rating on (ATNM) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Actinium Pharmaceuticals stock, see the ATNM Stock Forecast page.
Spark’s Take on ATNM Stock
According to Spark, TipRanks’ AI Analyst, ATNM is a Neutral.
Actinium Pharmaceuticals faces substantial financial challenges due to declining revenues, net losses, and negative cash flows, contributing to a low overall score. The technical analysis suggests a bearish trend, with the stock trading below key moving averages and negative MACD. The valuation is further weakened by a negative P/E ratio and absence of dividends. These factors significantly impact the stock’s attractiveness, resulting in a score towards the lower end of the scale.
To see Spark’s full report on ATNM stock, click here.
More about Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development of innovative therapies for patients with unmet medical needs.
Average Trading Volume: 205,596
Technical Sentiment Signal: Strong Sell
Current Market Cap: $43.67M
Find detailed analytics on ATNM stock on TipRanks’ Stock Analysis page.